Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02762396
Other study ID # 2015 / 1769
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2016
Est. completion date February 28, 2022

Study information

Verified date May 2023
Source Haukeland University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

NOR-SYS II is designed for finding the cause of acute ischemic stroke lesions in Young adults, age 15 to 49 years. Risk factors, arterial wall changes by intima-media thickness and plaques and consequences of stroke are examined by standardized diagnostics.


Description:

NOR-SYS II is as far as possible standardized concerning patients' history, ultrasound examination of pre-cerebral and femoral arteries, and standardized examinations performed by speech therapists, occupational therapists and physiotherapists. The ultrasound-protocol for carotid and femoral arteries is the same as previously performed in the NOR-SYS study. The Methods have been published before.


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date February 28, 2022
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender All
Age group 15 Years to 49 Years
Eligibility Inclusion Criteria: - Documented acute, arterial ischemic stroke - Speaks Norwegian fluently Exclusion Criteria: - Post-traumatic and procedure related stroke - Sinus venous thrombosis, sepsis and endocarditis - Serious co-morbidity, such as advanced cancer with "end-of-life stroke". - Patients mentally retarded or with severe psychiatric disease who do not accept the diagnosis and who would need sedation to perform clinical diagnostics.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Norway Dep. of Neurology Bergen

Sponsors (2)

Lead Sponsor Collaborator
Haukeland University Hospital Helsinki University Central Hospital

Country where clinical trial is conducted

Norway, 

References & Publications (1)

Fromm A, Thomassen L, Naess H, Meijer R, Eide GE, Krakenes J, Vedeler CA, Gerdts E, Larsen TH, Kuiper KK, Laxdal E, Russell D, Tatlisumak T, Waje-Andreassen U. The Norwegian Stroke in the Young Study (NOR-SYS): rationale and design. BMC Neurol. 2013 Jul 17;13:89. doi: 10.1186/1471-2377-13-89. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Established atherosclerosis The ultrasound protocol of the NOR-SYS study will be applied for carotid and femoral arteries. In addition angiographies will be done for patients with suspicious arterial disease. The measurements will be done within hospital stay after the acute stroke. Established atherosclerosis will serve as outcome measure for data collected during hospital stay and will be related to risk factors. The data will be presented one year after finishing the 5-years of inclusion of the whole study group.
Secondary New cardiovascular events Patients With different causes of ischemic stroke have different prognosis that is worst for recurrent stroke and other cardiovascular events for patients with atherosclerosis. One year after the stroke
Secondary Death Death fro all causes with subgroups of cardiovascular death, cancer and other causes of death will be registered One year after the stroke
Secondary Alive but not back to previous education or full-time job Not back to work because of stroke related problems. Standardized questionnaires will be used to collect information about education and work before stroke and the situation after 3 months and one year. The frequency and reasons why patients did not come back to their education situation or their job they did before the stroke are collected. We expect that it is still possible within a year from stroke onset, to specify the sort of problem related to stroke or unrelated to stroke. This may get more unspecific, the longer the time gets from stroke onset to follow-up. NOR-SYS II will focus on a particular group of patients that seem to function well but that struggle with unvisible problems such as tiredness and reduced capacity / energy to work. One year after the stroke